Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

24
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
24
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

43
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
43
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

32
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
32

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Editor's Choice - Focused Update on Paclitaxel Coated Technologies, from the 2024 European Society for Vascular Surgery (ESVS) Guidelines on the Management of Asymptomatic Peripheral Arterial Disease and Intermittent Claudication.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2026
Same author

A digital health program enhances walking capacity and health status in symptomatic peripheral artery disease.

European heart journal. Digital health·2026
Same author

Women with Abdominal Aortic Aneurysms Have a Different Pattern of Genetic Variability, Compared to Men.

Biomedicines·2026
Same author

Impact of nurse-led postoperative education on health outcomes following endovascular aortic repair: a randomized trial.

Scientific reports·2026
Same author

Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts.

International journal of chronic obstructive pulmonary disease·2026
Same author

Resetting the Game for Endovascular Treatment of Tosaka III Femoropopliteal In Stent Re-stenosis.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Sep 9, 2025

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.6K

Dispositivos recubiertos de paclitaxel frente a los no recubiertos para la revascularización endovascular

Mårten Falkenberg1, Stefan James2, Manne Andersson3

  • 1Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Lancet (London, England)
|September 3, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Los dispositivos recubiertos con paclitaxel no redujeron las amputaciones importantes en pacientes con enfermedad arterial periférica sometidos a revascularización endovascular. Este estudio no encontró diferencias significativas en las tasas de amputación entre los dispositivos con y sin recubrimiento.

Más Videos Relacionados

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.5K
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

566

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.6K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.5K
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

566

Área de la Ciencia:

  • Cirugía vascular
  • Cardiología intervencionista
  • Tecnologías de eliminación de drogas

Sus antecedentes:

  • Los dispositivos revestidos de fármacos son comunes en las intervenciones, pero su impacto en el riesgo de amputación en la enfermedad arterial periférica (EAP) no está bien definido.
  • Este estudio investiga el efecto de los dispositivos revestidos de fármaco en las tasas de amputación en pacientes con isquemia crónica que amenaza a los miembros (ICLC).

Objetivo del estudio:

  • Evaluar si los dispositivos recubiertos de paclitaxel reducen la tasa de amputaciones por encima del tobillo en pacientes con ILCL sometidos a revascularización endovascular infrainguinal.

Principales métodos:

  • Un ensayo controlado aleatorio pragmático a nivel nacional (SWEDEPAD 1) en el que participaron 2400 pacientes en 22 centros suecos.
  • Los pacientes con EAP de la categoría 4 a 6 de Rutherford recibieron globos/ stents recubiertos o sin recubrimiento de paclitaxel después de cruzar con éxito el alambre guía.
  • El criterio de valoración primario fue la amputación mayor ipsilateral (por encima del tobillo), analizado en la población de intención de tratamiento.

Principales resultados:

  • No se observaron diferencias significativas en las tasas de amputación ipsilateral mayor entre los dispositivos recubiertos de paclitaxel y los no recubiertos (HR 1,05 [95% IC 0,87-1,27]; p=0,61).
  • La mortalidad por cualquier causa tampoco mostró diferencias significativas entre los grupos (HR 1,04 [95% IC 0,92-1,17]; p=0,54).
  • El estudio incluyó a 2355 pacientes con una mediana de seguimiento de 2,67 años, con la mayoría de los pacientes presentando pérdida de tejido.

Conclusiones:

  • Los dispositivos recubiertos con paclitaxel no demostraron una reducción en las amputaciones ipsilaterales mayores en pacientes con ILCL sometidos a revascularización endovascular infrainguinal.
  • Los hallazgos sugieren que los dispositivos revestidos de fármacos actuales pueden no ofrecer una ventaja en la prevención de amputaciones en esta población de pacientes de alto riesgo.